CSIMarket Company Name, Ticker, Customers, else..


Fibrogen Inc   (NASDAQ: FGEN)
Other Ticker:  
 


 

Fibrogen Inc

FGEN's Financial Statements and Analysis



Fibrogen Inc reported in the forth quarter of 2024 net earnings per share of $0.18 an improvement compare to net loss per share of $-0.55 recorded a year ago and an improvement compare to net loss per share of $-0.17 realized in previous quarter.


forth quarter of 2024
Earnings Per Share Revenues
$ 0.18 $  0 Mill
$+0.73     $-27M    



Fibrogen Inc 's Revenue fell by 0 % in forth quarter of 2024 (Dec 31 2024) year on year, to $0 million and declined by sequentially.


Fibrogen Inc is

More on FGEN's Income Statement



Fibrogen Inc 's net income of $17.982 million in the forth quarter of 2024 increased from net loss of $-56.232 million IV. Quarter a year ago.

Sequentially Company turn into Profitability from net loss of $-17.084 million recorded in previous quarter.

More on FGEN's Growth

Fibrogen Inc Inventories
Inventories declined by -92.41 % to $3.16 million from IV. Quarter a year ago, sequentially inventories fell by -86.82 %. FGEN's Cash flow In the forth quarter of 2024 company's net cash flow was $22 million, capital expenditures grew by -0.251-43.82%, to $0 millions compare to same quarter a year ago

More on FGEN's Cash flow Statement


Fibrogen Inc does not pay out common stock dividend.

In trailing twelve-month period Fibrogen Inc payed $ -1.39 cash per share, on a free-cash flow basis .


Tangible Book value grew to $ -2.07 per share from $ -2.22.

Company repurchased 1.39 million shares or 1.38 % in Dec 31 2024.


• More on FGEN's Dividends

 Market Capitalization (Millions) 31
 Shares Outstanding (Millions) 99
 Total Debt (Millions $) 73
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -48
 Cash Flow (TTM) (Millions $) 39
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 333




Fibrogen Inc does not pay out common stock dividend.

In trailing twelve-month period Fibrogen Inc had negative $ -1.39 cash flow per share, on a free-cash flow basis .


Tangible Book value grew to $ -2.07 per share from $ -2.22.

Company repurchased 1.39 million shares or 1.38 % in Dec 31 2024.


• More on FGEN's Balance Sheets

 Market Capitalization (Millions) 31
 Shares Outstanding (Millions) 99
 Total Debt (Millions $) 73
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -48
 Cash Flow (TTM) (Millions $) 39
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 333
   


  News about Fibrogen Inc Earnings

Fibrogen Inc Witnesses Notable 155.062% Surge in Revenue Over Three-Month Fiscal Period Ending Sep 30, 2023



Fibrogen Inc, a biotech company operating in a seasonal nature of business, has recently reported some positive changes in its financial performance. However, a closer analysis reveals that these improvements might not be sustainable, leaving investors concerned about the future prospects of the company. This bearish article will delve into the recent fiscal period results of Fibrogen Inc and examine key indicators that suggest challenges ahead.
Declining Loss per Share but Concerning Net Loss:
While Fibrogen Inc managed to decrease its loss per share from $-0.98 a year ago to $-0.65 in the most recent fiscal period, the company still reported a substantial net loss of $-63.615 million. Thi...

Despite Revenue Surge, Fibrogen Inc Falls Short in Q2 2023: Increased Losses Rattle Investors

Fibrogen Inc, a major player in the pharmaceutical preparations industry, has reported its financial results for the second quarter of 2023. Despite an increase in revenue of 48.692% to $44.32 million compared to the same period last year, the company's loss per share also increased to $-0.90 per share. This can be seen as a setback for Fibrogen Inc, as their peers in the industry experienced an average top-line elevation of only 2.30% from the second quarter of 2022.
In comparison to the preceding reporting period, where the company reported revenue of $36.16 million and a loss per share of $-0.81, the second quarter of 2023 saw a larger net loss of $-87.680 million, compared to $-72.624 million the pre...

Fibrogen Inc's Financial Woes Deepen: Innovation Takes a Hit in Recent Fiscal Period

Fibrogen Inc is a pharmaceutical and biotechnology company that specializes in the development of innovative therapies for the treatment of serious and life-threatening diseases. With a focus on research and development, Fibrogen Inc has been able to bring numerous drugs to the market that have helped to improve the lives of countless patients around the world.
Despite its reputation for innovation, Fibrogen Inc has experienced some financial troubles in recent years. The most recent fiscal period, for example, saw a significant increase in losses compared to the year prior. Specifically, Fibrogen Inc's loss per share rose from $-0.68 to $-0.81, and the company's overall net loss increased from $-63.205 ...


Date modified: 2025-03-19T03:32:21+00:00





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com